Current Share Price data for TruScreen Group Limited (NZX:TRU ASX:TRU)
Cervical cancer can and should be prevented.
TruScreen provides an accurate, real-time primary screening solution.
Our screening solution is ideal for communities that can’t access conventional laboratory-based screening methods. It is affordable and easy to learn.
Our purpose is to ensure that all women of screening age – no matter who or where they are – have access to quality screening.
TruScreen manufactures and owns all rights to the TruScreen Cervical Cancer Screening System. The system comprises a medical device and AI-enabled process designed to detect, in real-time, the presence of pre-cancerous and cancerous tissue on the cervix.
TruScreen’s focus markets are low and-middle income countries (LMICs) where there is a lack of organised cervical cancer screening and the required infrastructure.
TruScreen is pleased to provide a copy of its August 2023 Stakeholder Newsletter.
TruScreen Group Limited (NZX/ASX:TRU) is pleased to report a 100% growth in sales over the same quarter year on year and a 73% growth in sales of Single Use Sensor (SUS) for the same period.
TruScreen opto-electrical technology recognized in China Cervical Cancer Screening Guideline by top national expert organisation
TruScreen Group Limited (NZX/ASX: TRU), advises that its Annual Meeting will be held in the Boardroom of Link Market Services, Level 30 PWC Tower 15 Customs Street West Auckland and online at www.virtualmeeting.co.nz/tru23 on Tuesday 29 August 2023.
TruScreen Group Limited (NZX: TRU) has released its Annual Report for the year ended 31 March 2023.
New China cervical cancer screening guideline announced by CSCCP to include Truscreen’s optical electrical technology. First national medical guideline in the world to recommend TruScreen technology, expected to drive further sales.
TruScreen Recognised in Authoritative China Blue Paper – “Cervical Cancer Three Stage Standardised Prevent and Treat”
TruScreen to be listed on the Innovation Register by the Polish Ministry of Health. COGA trial manuscript in review for publication in the Journal of the American Medical Association (15,661 patients in trial). Saudi Arabia, Al Habib clinical evaluation manuscript in review for publication in the European Journal of Gynaecology Oncology (507 patients in trial). China cervical cancer screening at pre-Covid levels. 20 devices shipped in April 2023 with further 20 devices to be shipped in May.
Truscreen Group Limited is pleased to advise that the leading private medical services provider , Dr. Sulaiman Al-Habib Medical Group, has recently completed the analysis of results from its cervical screening clinical evaluation of TruScreen Ultra and Liquid Based Cytology (LBC).
Pitt Street Research
TruScreen Group Ltd (NZX/ASX: TRU) is a medtech company that is commercialising the TRU system.
TruScreen Group is dual-listed on the NZX and ASX. All of our announcements are available through our website, or via the NZX and ASX platforms.View announcements
TruScreen has a wealth of experienced, highly skilled professionals across its Directors, Executive Team, Medical Advisory Board, and Research & Development Team.